发布求助
文献互助 智能选刊 最新文献

Issues in emerging health technologies最新文献

筛选
英文 中文
Transcatheter closure of atrial septal defects. 房间隔缺损经导管闭合术。
Issues in emerging health technologies Pub Date : 2003-05-01
David Hailey, Leigh-Ann Topfer
{"title":"Transcatheter closure of atrial septal defects.","authors":"David Hailey,&nbsp;Leigh-Ann Topfer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Until recently, surgical repair was the standard treatment for an ostium secundum atrial septal defect (ASD), a common congenital heart defect. Closing ASDs using a device inserted via a catheter now offers another option for some patients. Limited comparative data indicate that newer approaches to transcatheter repair have a higher failure rate than that for surgery, but short-term complication rates are lower. Evidence from long-term follow-up of patients with device closure of ASDs is not yet available. Equipment and procedure costs may be higher for transcatheter closure than for surgery, but overall costs may be reduced through avoiding intensive care unit costs and through shorter hospital stays.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 47","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22418840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atomoxetine for attention deficit/hyperactivity disorder. 托莫西汀治疗注意缺陷/多动障碍。
Issues in emerging health technologies Pub Date : 2003-05-01
Kirsten Garces
{"title":"Atomoxetine for attention deficit/hyperactivity disorder.","authors":"Kirsten Garces","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Seven randomized, double-blinded, controlled trials in children, adolescents and adults have shown that atomoxetine improves attention deficit/hyperactivity disorder (ADHD) symptoms compared to placebo. There is no evidence that atomoxetine has greater efficacy or a better safety profile than currently used therapy. Atomoxetine has been submitted for regulatory approval in Canada and is currently approved in the US. The price of atomoxetine in Canada has not been established.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 46","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22389610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alefacept: potential new therapy for patients with moderate-to-severe psoriasis. alfacept:治疗中重度牛皮癣的潜在新疗法。
Issues in emerging health technologies Pub Date : 2003-04-01
Vijay K Shukla
{"title":"Alefacept: potential new therapy for patients with moderate-to-severe psoriasis.","authors":"Vijay K Shukla","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alefacept is a new biotechnology product designed for the treatment of patients with chronic plaque-type psoriasis who have disease severe enough to make them eligible for phototherapy or systemic therapy. In two randomized controlled phase III trials of patients with moderate-to-severe disease, alefacept showed a modest but statistically significant increase in the number of responders compared to placebo. Alefacept's dose-dependent CD4+ T lymphocyte-depleting effect requires monitoring; however, no association has been found between this adverse effect and serious adverse events, particularly infection. Due to lack of direct comparative data, it is difficult to predict exactly how alefacept will fit into the current rotational psoriasis therapy paradigm.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 45","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2003-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22328415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vacuum assisted wound closure therapy. 真空辅助伤口闭合治疗。
Issues in emerging health technologies Pub Date : 2003-03-01
Andrea Fisher, Bruce Brady
{"title":"Vacuum assisted wound closure therapy.","authors":"Andrea Fisher,&nbsp;Bruce Brady","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vacuum assisted closure (VAC) therapy is designed to promote the formation of granulation tissue for faster healing in the wound beds of patients with acute and chronic wounds. Four controlled trials and one interim analysis provide poor quality data and weak evidence that VAC therapy may be superior to conventional methods used in healing wounds. Complications with VAC therapy are uncommon. Studies are needed to evaluate the effectiveness of VAC therapy when the types of dressings are the same for patients in the groups being compared and VAC therapy is the only differing intervention.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 44","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22304696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multislice/spiral computed tomography for screening for coronary artery disease. 多层/螺旋计算机断层扫描对冠状动脉疾病的筛查。
Issues in emerging health technologies Pub Date : 2003-02-01
Keng Ho Pwee
{"title":"Multislice/spiral computed tomography for screening for coronary artery disease.","authors":"Keng Ho Pwee","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Multislice computed tomography (MSCT) and spiral (or helical) computed tomography (CT) are designed to provide faster images with better resolution than conventional CT scanning. MSCT and spiral CT have been used to quantify calcification in the coronary arteries, in an effort to link this to coronary artery disease. Long-term studies on clinical outcomes of people screened with MSCT or spiral CT are lacking, as are comparisons with established screening modalities like risk factor algorithms. Low specificity gives rise to concern over false positive results. False positives may cause harm (and expense) due to inappropriate and invasive follow-up. One study was identified in which spiral CT was compared with electron beam CT (EBCT) to evaluate coronary calcifications in 33 asymptomatic individuals, giving a sensitivity of 74% and a specificity of 70%. There is insufficient evidence at this time to suggest that asymptomatic people derive clinical benefit from undergoing coronary calcification screening using MSCT or spiral CT scanning.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 43","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2003-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22274841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imatinib mesylate for chronic myeloid leukemia: what do we really know? 甲磺酸伊马替尼治疗慢性髓性白血病:我们到底知道些什么?
Issues in emerging health technologies Pub Date : 2002-12-01
Don Husereau
{"title":"Imatinib mesylate for chronic myeloid leukemia: what do we really know?","authors":"Don Husereau","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Imatinib mesylate (GleevecTM) is a tyrosine kinase inhibitor, one of a new class of anticancer drugs called signal transduction inhibitors. A systematic review of case-series reports shows imatinib, when indirectly compared to conventional therapy, improves overall 12-month survival, but not surrogate outcomes, in individuals with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in myeloid-blast crisis, and accelerated phase. Surrogate outcomes, but not overall survival, were improved in chronic phase disease. Preliminary data from one randomized controlled trial suggest imatinib has a greater impact on surrogate outcomes compared to the combination of interferonalpha and cytarabine in patients undergoing treatment for chronic phase Ph+CML, however, it is not yet known whether it prolongs or improves quality of life.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 42","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22164850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hand-carried ultrasound units for point-of-care cardiac examinations. 用于即时心脏检查的手持超声装置。
Issues in emerging health technologies Pub Date : 2002-10-01
David Hailey, Leigh-Ann Topfer
{"title":"Hand-carried ultrasound units for point-of-care cardiac examinations.","authors":"David Hailey,&nbsp;Leigh-Ann Topfer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several hand-carried ultrasound units have been developed for point-of-care cardiac examination. Limited small comparative studies indicate that these devices are more accurate than physical examination. Though their diagnostic performance is generally inferior to standard echocardiography, there appears to be close agreement for some conditions. Operator training in the performance and interpretation of tests using these ultrasound devices is vitally important. The place of these devices in health care will depend on their compatibility with individual practice, their cost, reimbursement decisions and further technical developments.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 41","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22074419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug eluting stents: managing coronary artery stenosis following PTCA. 药物洗脱支架:治疗PTCA后冠状动脉狭窄。
Issues in emerging health technologies Pub Date : 2002-10-01
Kirsten Garces
{"title":"Drug eluting stents: managing coronary artery stenosis following PTCA.","authors":"Kirsten Garces","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Drug eluting stents (DES) release drugs that inhibit tissue growth in narrowed coronary arteries in an effort to prevent restenosis, a renarrowing of the artery. Several types of DES are under investigation in clinical trials; however, none are currently approved for use in Canada. Preliminary trial data are encouraging, demonstrating greater lumen diameter and reduced restenosis with DES versus uncoated stents. If DES prove to be more effective than uncoated stents in the treatment and/or prevention of restenosis, this technology may diffuse rapidly. The total health care costs, including the cost of the stents, post-intervention therapy and possible re-intervention costs, will require assessment to determine the ultimate impact of DES.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 40","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2002-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22071252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure: is there a role for angiotensin II receptor blockers? 心力衰竭:血管紧张素II受体阻滞剂是否有作用?
Issues in emerging health technologies Pub Date : 2002-09-01
Michel Boucher, Johnny Ma
{"title":"Heart failure: is there a role for angiotensin II receptor blockers?","authors":"Michel Boucher,&nbsp;Johnny Ma","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Angiotensin II receptor blockers (ARBs) directly inhibit the angiotensin II type 1 receptors, which suppresses the renin-angiotensin-aldosterone system (RAAS). Six ARBs are approved in Canada for the treatment of hypertension, none are yet approved for the treatment of heart failure (HF). Evidence comparing ARBs to angiotensin converting enzyme inhibitors (ACEIs) in HF is still limited. A recent meta-analysis of 17 clinical trials could not confirm that ARBs are superior to ACEIs in reducing either mortality or hospitalization in HF patients. ARBs may be used as an alternative in HF patients intolerant of ACEIs. A meta-analysis indicates that, compared to using an ACEI alone, adding an ARB to an ACEI carries the potential for additional benefits in terms of reduced hospitalization, but not mortality. However, the FDA determined there is currently insufficient evidence of such additional benefit when valsartan is combined to an ACEI in patients with HF.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 38","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2002-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22000507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure: is there a role for angiotensin II receptor blockers? 心力衰竭:血管紧张素II受体阻滞剂是否有作用?
Issues in emerging health technologies Pub Date : 2002-09-01 DOI: 10.4212/CJHP.V56I2.414
M. Boucher, J. Ma
{"title":"Heart failure: is there a role for angiotensin II receptor blockers?","authors":"M. Boucher, J. Ma","doi":"10.4212/CJHP.V56I2.414","DOIUrl":"https://doi.org/10.4212/CJHP.V56I2.414","url":null,"abstract":"Angiotensin II receptor blockers (ARBs) directly inhibit the angiotensin II type 1 receptors, which suppresses the renin-angiotensin-aldosterone system (RAAS). Six ARBs are approved in Canada for the treatment of hypertension, none are yet approved for the treatment of heart failure (HF). Evidence comparing ARBs to angiotensin converting enzyme inhibitors (ACEIs) in HF is still limited. A recent meta-analysis of 17 clinical trials could not confirm that ARBs are superior to ACEIs in reducing either mortality or hospitalization in HF patients. ARBs may be used as an alternative in HF patients intolerant of ACEIs. A meta-analysis indicates that, compared to using an ACEI alone, adding an ARB to an ACEI carries the potential for additional benefits in terms of reduced hospitalization, but not mortality. However, the FDA determined there is currently insufficient evidence of such additional benefit when valsartan is combined to an ACEI in patients with HF.","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":"38 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2002-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70309851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书